BiPar Sciences

BiPar Sciences, Inc. is a privately held biopharmaceutical company pioneering novel tumor-selective therapies aimed at addressing the significant unmet needs of cancer patients. In addition to BSI-201, the company has two compounds in preclinical development: BSI-401, a follow-up PARP inhibitor candidate being investigated as an oral treatment for pancreatic cancer, and BSI-302, a novel anti-tubulin agent targeting cancer cells based on the role of thyroid hormones in cell proliferation and death.